Outcomes

Yale Cancer Center and our partner, Smilow Cancer Hospital, acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers.  The latest performance data for breast center is listed below.


Breast MeasuresExpected Estimated Performance Rates (percentage)Yale Performance 2012Yale Performance 2013Yale Performance 2014
Tamoxifen or third generation aromotase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer (Accountability)90%93.5092.5094.20
Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes (Accountability)90%92.9093.8091.20
Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability)90%95.9095.5093.50
Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability)90%93.5093.3094.90

**Higher percentage is better